Right now I can’t find any resources where they mention their sales breakup in insecticides, fungicides, and herbicides but BCIL’s main products include Chlorpyrifos, Pymetrozine, Azoxystrobin, and Fipronil. The top three products of the company, Chlorpyrifos, Azoxystrobin, and Fipronil, formed around 82% of the company’s revenues in FY23
Posts in category Value Pickr
Apcotex Industries – monopoly in Synthetic Rubber? (30-01-2024)
Apcotex(dec 2023, investor presentation)
• Quarterly volume growth of 21% YoY, 8% volume drop QoQ mainly due to NBR & HSR
• Highest Quarterly export volume growth of 98% YoY led by Nitrile Latex, Carpet and Construction
• Revenue growth of 10%, due to increased volumes in spite of challenging market conditions
• EBITDA: decreased 17% YoY due to lower margins in NBR, XNB and Paper, and there was no significant inventory loss/gain
in this quarter
• PBT and PAT lower YoY, because of increase in Depreciation and Interest Cost due to new expansion projects.
Disc…invested
Skipper Ltd., (Power and Water) a moat in making? (30-01-2024)
The company mentioned it would call for it. Not sure how it happens. My guess is after you are sure of the number allotted to you , you can make the rest of the payment. I have already made my application.
If you make mistake in ASBA or miss the dead line I’m afraid I don’t think you can make amends.
maybe someone knowledgeable can pitch in.
Orchid Pharma Ltd (30-01-2024)
Orchid Pharma’s ‘Exblifep’ granted European Medicines Agency
approval – A landmark achievement for India’s pharmaceuƟcal
Industry
Here is the company filing on NSE & BSE
Hope it helps.
Skipper Ltd., (Power and Water) a moat in making? (30-01-2024)
After paying 25% how is the remaining money called, is it generally in installments.
Suppose if I miss the due date for payment of rights or there was an error in my Asba application can I mail them and pay the remaining amount.
52 week highs and all time highs strategy (30-01-2024)
UPDATE: Powermech Projects 2900-5200 ATH,
- Base breakout seen today with volumes rising over past week.
- Weekly RSI healthly at 74.
- Trailing the stock is working. Drawdowns are a part of the journey, two 30%+ drawdowns seen in the move up.
Safe to assume bullish bias ahead.
Wockhardt – A story with twist and turn (30-01-2024)
https://www.ema.europa.eu/en/medicines/human/EPAR/exblifep
Orchid Pharma’s ‘Exblifep’ received positive recommendation from EMA.
The drug is cefepime+enmetazobactam, indicated for uses in
- Complicated urinary tract infections (cUTI), including pyelonephritis
- Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)
Can there be an impact on WCK 5222’s market size, given that one of the uses for this drug can be for Hospital acquired infections like VAP?
Kirloskar Electric – A Turnaround Bet? (30-01-2024)
Is there any news on this company? 20% UC today
Federal Bank – A Turnaround banking Story? (30-01-2024)
still in the previous quarter, there was a notable rise in the investment made by FII in Federal Bank. Its among top in banking sector in terms of fii investment
Orchid Pharma Ltd (30-01-2024)
Can this have any impact on the market size of WCK 5222 (cefepime+zidebactam) developed by Wockhardt, mainly targeting hospital acquired infections, ventilator associated pneumonia and other gram negative suberbugs?